Gufic Biosciences Limited (BOM:509079)
370.05
+9.85 (2.73%)
At close: Jun 16, 2026
Gufic Biosciences Revenue
In the fiscal year ending March 31, 2026, Gufic Biosciences had annual revenue of 9.44B INR with 15.15% growth. Gufic Biosciences had revenue of 2.52B in the quarter ending March 31, 2026, with 22.83% growth.
Revenue
9.44B
Revenue Growth
+15.15%
P/S Ratio
3.93
Revenue / Employee
6.36M
Employees
1,484
Market Cap
37.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 9.44B | 1.24B | 15.15% |
| Mar 31, 2025 | 8.20B | 131.40M | 1.63% |
| Mar 31, 2024 | 8.07B | 1.16B | 16.80% |
| Mar 31, 2023 | 6.91B | -885.35M | -11.36% |
| Mar 31, 2022 | 7.79B | 2.91B | 59.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 22.65B |
| FDC Limited | 21.71B |
| Morepen Laboratories | 18.06B |
| Sanofi India | 17.74B |
| Hikal | 17.13B |
| Bliss GVS Pharma | 8.68B |
| Venus Remedies | 7.70B |
| Kwality Pharmaceuticals | 5.03B |
Gufic Biosciences News
- 15 days ago - Gufic Biosciences Transcript: Q4 25/26 - Transcripts
- 15 days ago - Gufic Biosciences Quarterly report: Q4 2026 - Filings
- 15 days ago - Gufic Biosciences Slides: Q4 2026 - Filings
- 4 months ago - Gufic Biosciences Transcript: Q3 25/26 - Transcripts
- 4 months ago - Gufic Biosciences Quarterly report: Q3 2026 - Filings
- 4 months ago - Gufic Biosciences Slides: Q3 2026 - Filings
- 7 months ago - Gufic Biosciences Transcript: Q2 25/26 - Transcripts
- 7 months ago - Gufic Biosciences Quarterly report: Q2 2026 - Filings